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Abstract Epidemiologic and clinicopathologic features,
therapeutic strategies, and prognosis for acinic cell carci-
noma of the major and minor salivary glands are critically
reviewed. We explore histopathologic, histochemical,
electron microscopic and immunohistochemical aspects
and discuss histologic grading, histogenesis, animal mod-
els, and genetic events. In the context of possible diag-
nostic difficulties, the relationship to mammary analog
secretory carcinoma is probed and a classification is sug-
gested. Areas of controversy or uncertainty, which may
benefit from further investigations, are also highlighted.
Keywords Acinic cell carcinoma  Pathology  Salivary
glands  Therapy  Prognosis  Mammary analog secretory
carcinoma
Introduction
The International Head and Neck Scientific Group regar-
ded that a series of articles revisiting the major epithelial
salivary malignancies in the light of contemporary
knowledge would be of interest. In this respect, an article
on adenoid cystic carcinoma [1] as well as on mucoepi-
dermoid carcinoma has recently been published [2] and is
now followed by the present article on acinic cell carci-
noma (AcCC). This was deemed appropriate as both
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mucoepidermoid carcinoma and AcCC are characterized
by innate acinar differentiation and an often favorable
prognosis [2, 3], features interesting enough to result in
intensive study and accumulating literature. The structure
of the present article and the principles of our approach are
similar to those of the previous [1, 2]. We review salivary
gland AcCC, critically appraising the recent literature and
integrating recent findings into the existing knowledge
base, predicated on extensive clinical experience, epi-
demiological, clinicopathological, imaging and genomic
aspects that determine our management decisions and
consequent prognosis.
Definition and brief historical survey
The World Health Organization (WHO) currently defines
salivary AcCC as ‘‘a malignant epithelial neoplasm of
salivary glands in which at least some of the neoplastic
cells demonstrate serous acinar cell differentiation, which
is characterized by cytoplasmic zymogen secretory gran-
ules. Salivary ductal cells are also a component of this
neoplasm’’ [3]. Commitment to the characterisation of the
secretory granules as zymogen and interpretation of the
cells lacking obvious secretory granules as ductal cells may
be criticized. The definition is, however, useful because it
emphasizes the presence of a structural component other
than serous-like acinar cells.
Godwin et al. [4] traced the earliest cases back to the
1890s, Nasse [5] being generally regarded as having
described the first case in 1892 as a ‘blue dot tumor’,
because of the appearance of what we now know are
intracytoplasmic zymogen granules. It is likely that the
serous cell phenotypes and apparent circumscription of the
tumor accounted for the description of serous cell or acinar
adenomas in the earlier literature [6]. Buxton et al. [7]
probably described the first cases of AcCC with a
straightforward malignant behavior. Foote and Frazell [8]
are usually credited with the ‘‘modern’’ morphological
descriptions of the tumor, but it was oral pathologists who
subsequently took the lead. Their efforts culminated in
1965 when a group led by Abrams published a detailed
clinicopathologic study of 77 cases of AcCC of major
salivary glands from the archives of the Armed Forces
Institute of Pathology (AFIP), which defined particular
growth patterns and tumor-cell types [9]. In the 1970s, the
publication of the World Health Organization (WHO)
histological classification of salivary gland tumors [10] and
also the seminal volume by Thackray and Lucas [11]
spearheaded the now discarded term ‘‘acinic cell tumor’’
(with the suggestion to only use the term ‘‘carcinoma’’ if
the tumor ‘‘happens to metastasize’’) and general patholo-
gists with a special interest in head and neck entered the
field [12–14]. Oral pathologists responded by defining
clinicopathologic features of AcCC in minor salivary
glands [15, 16], revisiting the AFIP archives of 294 cases
[17] and aptly presenting the experience in the AFIP atlas
[18]. The accumulating clinicopathologic experience
together with investigative approaches using modalities
such as electron microscopy, histochemistry, and
immunohistochemistry substantially increased our under-
standing of AcCC. There seemed little wishing for and
AcCC did not feature in reviews of advances in salivary
pathology [19, 20]. However, the notion of AcCCs entirely
composed of non-descript cells lacking secretory granules,
illustrative per se of the inherent difficulties in precisely
characterizing cells of simple phenotypes, should warrant a
certain apprehension. This proved well founded in 2010
when the so-called mammary analog secretory carcinoma
(MASC), a low-grade salivary malignancy that is histo-
logically similar to AcCC of non-serous acinar cells and
harbors the ETV6–NTRK3 translocation, was reported [21].
Subsequently Bishop et al. [22] re-classified most non-
parotid AcCC of non-serous cells as MASCs. Whether
MASC is a distinct entity remains to be established, which
is discussed below (see ‘‘Proposed classification’’), but is a
concept that should be considered when the earlier litera-
ture is reviewed.
Whereas most clinicians still associate AcCC to a good
prognosis, recent studies increase our awareness of the
propensity of this tumor for lymphatic invasion and distant
metastases, developing in a protracted and unpre-
dictable clinical course. Indeed, (late) distant metastases to
the lungs, pleura, brain, peritoneum, paraaortic, paratra-
cheal, and mediastinal lymph nodes, as well as cutaneous
metastases, have been described, especially in the de-dif-
ferentiated subgroup of AcCC, nowadays commonly
referred to as ‘‘acinic cell carcinoma with high-grade
transformation’’ [13, 23–25].
Epidemiology
Unfortunately, the highly desirable population-based
studies provide little information beyond incidence and
survival [26–28]. Institution-based studies are more
detailed, but report limited number (up to 35) of cases
collected over a long period and treated without standard-
ized protocols, which makes statistical evaluation difficult
[29–32].
In western countries, salivary gland carcinomas (SGCs)
account for about 4 % of all head and neck cancers,
approximately 80 % occurring in the parotid [33]. About
one out of six parotid cancers is AcCC [34], which is
supported by a nationwide study in Netherlands, where
15 % of parotid malignancies were AcCC [26]. A recent
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surveillance, epidemiology, and end results (SEER) anal-
ysis from 1973 to 2009 indicated that AcCC comprises
11 % of all salivary gland malignancies, with an average
annual incidence of 0.13 cases per 100,000 patients per
year during the 36 years the study encompassed [28].
Incidence trend analysis, stratified for gender and race,
indicated a significant annual increase (annual percentage
change of 1.06 %) [28]. Rather than being genuine, this
trend is attributable to improved and increasingly widely
known histopathologic diagnostic criteria. The SEER
analysis also indicated a higher average annual incidence
for females (0.15 cases per 100,000 patients) in comparison
to males (0.11 cases per 100,000 patients). This correlates
with a consistent slight female predominance in institu-
tional [35, 36] and population-based series. The latter
report female:male incidence ratios ranging from 1.43:1 to
1.57:1 [27, 28, 37].
The age distribution of AcCC seems quite even
throughout all decades, with one-third of patients below the
age of 40, one-third between 40 and 59, and one-third
above 60 years [28]. This corresponds to the findings in a
series from the MD Anderson Cancer Center (MDACC)
[36]. With a median age at diagnosis of 52 years, AcCC
tends to occur at a younger age than other SGCs [27].
Children are very rarely affected by SGCs, but when they
are, the most frequently observed histologic type is
mucoepidermoid carcinoma, followed by AcCC [38, 39].
AcCC is predominantly diagnosed in whites (85 %) and
less frequently in blacks (7 %) or other racial backgrounds
(8 %) [28, 32]. Very little is known regarding risk factors
for AcCC. Although familial predisposition and previous
radiation exposure have been considered, no cases were
noted among long-term atomic bomb survivors [40] and
descriptions of familial occurrence are very sparse [41].
One case has been reported in an individual with Cowden
syndrome [42], and there is a recent case report of AcCC of
the breast developing in a BRAC1 mutation carrier [43].
Clinical features
In the major salivary glands, the parotid is most commonly
affected, the typical clinical presentation being a slow-
growing swelling. Symptoms are often lacking, which
often results in late diagnosis. Pain or fixation to sur-
rounding tissues herald poor prognosis [35]. Nodal
metastasis is extremely uncommon at presentation. In the
MDACC series mentioned above, only 12 of 155 patients
(8 %) had nodal disease, even when 75 % presented with
persistent or recurrent AcCC [36]. In another series from
the Memorial Sloan Kettering Cancer Center (MSKCC),
three out of 35 patients (9 %) presented with nodal disease;
also uncommon in this series were pain (n = 5; 13 %) and
cranial nerve VII dysfunction (n = 1; 3 %) [32].
AcCC is far less common in minor salivary glands. A
population-based report identified 736 cases of parotid
AcCC (91 %) compared to only 42 cases (5 %) in other
major and 35 cases (4 %) in minor salivary glands [27]. In
addition, AcCC of minor salivary glands accounts for about
9 % in a SEER database [44]. The trend is also a feature of
institutional series [36] and in case reports [45, 46].
Whether this relates to a generally decreased proportion of
serous acinar cells in normal minor salivary glands, is
unknown. In contrast to other types of minor SGCs, which
mainly occur in the palate, [47] AcCC mainly occurs in the
buccal mucosa and upper lip [31]. A small minority of
AcCC arises in the sinonasal area [44, 48] or the larynx
[49], but these are outside the scope of the present article.
Bilateral AcCC is highly controversial. While some urge
caution or are unconvinced, [50] others suggest that AcCC
is the most frequently reported bilateral SGC [51, 52]. For
completeness, non-salivary AcCC have been described in
the lacrimal gland, pancreas, and breast. The tumors in the
pancreas are referred to as acinar cell carcinoma [43, 53].
Pre-operative assessment
Surgery is the first and most important step in the man-
agement, if technically feasible and if there are no medical
contraindications. Pre-operative assessment of AcCC is
similar to that of other tumors of the major salivary glands
and involves imaging and needling procedures. Since
AcCC often presents as a swelling, with little to suggest
malignancy, pre-operative assessment aims at assessing
localization, extent, indicators of malignancy, as in the case
of parotid AcCC, these factors will determine the risk to
the facial nerve during surgery [54]. Imaging can be
omitted without detriment to further management in
mobile, circumscribed tumors where localization and
extent are clinically obvious. It is strongly recommended
when a glandular swelling is associated with impaired
mobility or when involvement of deeper structures/cranial
nerves is suspected [55–58]. For AcCC, impaired mobility
is typically seen in larger tumors or, more frequently, in
local recurrences.
Pending on particular circumstances, pre-operative
imaging includes ultrasound (US) (Fig. 1), computed
tomography (CT), magnetic resonance imaging (MRI)
(Fig. 2), and positron emission tomography (PET) [54].
A recent study comparing US and CT indicated that
most primary AcCCs show ‘benign’ imaging features
reconcilable with the often favorable prognosis of the
tumor. On US, AcCC appeared lobular, rather defined,
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hypoechoic, heterogeneous and poorly vascularized
(Fig. 1); on CT, it appeared regular and variably defined
with limited heterogeneous enhancement [59]. The study
supported the earlier findings of Suh et al. [60], who
described CT qualities of AcCC in relation to histopatho-
logic features.
MRI is superior to CT in assessing parotid, stylomastoid
foramen and any facial nerve invasion/perineural extension
(Fig. 2) [56, 57, 61, 62]. It is particularly indicated for
patients with recurrent or residual AcCC and favored in
tertiary centers where these patients are usually referred.
As an example, 75 % of patients treated in MDACC had
residual or recurrent disease; for these patients a mean-
ingful statement on the feasibility of further treatment
without an adequate was judged impossible without MRI
[36].
PET with or without CT should be considered in clini-
cally/radiologically suspected or needling-procedure pro-
ven, advanced stage, salivary malignancies, to exclude
gross, distant disease. This is a very uncommon situation in
AcCC [54]. PET may be, however, recommended post-
operatively when a histologic diagnosis of AcCC with
high-grade transformation is established [63–65].
The needling procedures are usually ultrasound guided
and include fine needle aspiration cytology (FNAC) and
core biopsy (USCB). FNAC is an integral part of the pre-
operative assessment, and it has been repeatedly empha-
sized that the value of FNAC reflects the experience of the
operator, yield of material and expertise of the pathologist
interpreting the aspirate, which in turn are influenced by
the number of salivary tumors managed in particular
institutions. Data on the role of FNAC in diagnosing AcCC
(Fig. 3a) are limited. Overall sensitivity is low, often due to
a false negative interpretation of tumoral acinar structures
(see ‘‘Pathology’’) as normal parenchyma. Accuracy of
17 % (two out of 12) [30] and a specificity of 27 % (four
out of 15) [66] have been reported. Cystic tumors (see
‘‘Pathology’’ section) present additional problems, since
obtained aspirates may be hypocellular and misinterpreted
as a benign salivary cyst. Centrally placed nuclei, less
Fig. 1 US image of a parotid AcCC (asterisk). Note the homoge-
neous aspect and the well-demarcated borders of the tumor
Fig. 2 Axial T2-weighted MR image of a deep-lobe parotid AcCC
(arrow). T2 hyperintensity as seen in pleomorphic adenoma, regular
borders
Fig. 3 Aspirate showing
aggregates of tumor cells
stained with Giemsa (a).
Tubulo-acini of tumor cells
immunohistochemically stained
for DOG1 (b)
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demarcated cell borders and lack of association with adi-
pocytes may be helpful in distinguishing AcCC with
prominent serous acinar cell differentiation from normal
acini, [18] and the presence of large nuclei with distinct
nucleoli and binucleated cells are further alerting features
[67]. FNAC diagnosis of AcCCs entirely composed of non-
descript cells lacking secretory granules is more difficult.
The accuracy of FNAC seems higher for AcCC with high-
grade transformation (see ‘‘Pathology’’) [64], but this likely
reflects detection of obviously malignant cells rather than
identification of conventional AcCC. USCB has been less
explored, but further immunohistochemistry (see below)
can be applied to the material thus obtained (Fig. 3b); a
modest 50 % accuracy may be obtained with frozen sec-
tions of open biopsies [66].
Pathology
This remains the gold standard for the diagnosis of AcCC.
Macroscopical appearances
Salivary AcCCs are often rounded, circumscribed, and
even variously encapsulated masses [18, 68]. Lobulation
can be seen, whereas infiltrative growth into adjacent tis-
sues is uncommon. Pending on site, ACCs often range
from\1.0 to 4.0 cm. Sizes up to 13.0 cm have been
reported [18], possibly reflecting delayed diagnosis or
neglected cases. Tumors of minor salivary glands are
usually smaller due to earlier detection. Upon dissection,
AcCCs are rubbery and solid or variably cystic (Fig. 4).
Solid areas are grayish-white or tan with areas of
hemorrhage. Necrosis together with multiple, variously
separated masses and infiltrative qualities are not uncom-
mon in recurrences [4, 68].
Histology
This is outlined in Table 1. The following discussion is
based in standard references and personal experience [3, 9,
11, 12, 14, 15, 17, 18, 68–70].
On routinely prepared sections of resection specimens
examined at scanning magnification, AcCCs are variously
solid or cystic growths that appear hematoxyphilic or
eosinophilic (Fig. 5), the latter influenced by the ser-
ous:non-serous cell phenotype ratios and/or proportion of
fibrous stroma. Although the tumors are usually non-en-
capsulated and asymmetrical, they are often lobulated and
variously circumscribed; even a fibrous capsule may be
seen. Encapsulated, hematoxyphilic tumors would account
for Nasse’s ‘blue dot tumor’ [5], and erroneous diagnoses
of serous cell or acinar adenoma.
Tumors of minor salivary glands are centered in the
submucosa where they are partly surrounded by salivary
lobules; they may involve main ducts (Fig. 5a). Similar to
mucoepidermoid carcinoma [2], ‘flooding’ of the lamina
propria is unusual. Parotid AcCCs are often superficially
located—hence, partly surrounded by glandular lobes
(Fig. 5b, c).
Figure 5 also allows appreciation of various silhouettes
of AcCC. Tumors irregularly penetrating salivary lobules,
soft tissues or bone, ‘satellites’ invading far ahead of the
main growth, perineurial invasion and necrosis are not
frequent.
Various patterns of growth can be seen. They include
solid, microcystic, follicular, papillary (Fig. 6), and cystic
(Fig. 5c); and occur alone or in combination [17, 71].
About a quarter of AcCCs are solid with an easily rec-
ognized histology. The tumor parenchyma therein is
organized in packed aggregates, largely of differentiated,
serous-like cells laden with hematoxyphilic, secretory
granules (Fig. 6a). The solid pattern is characterized by
sheets of cells separated by thin fibrovascular strands, and
thus often appears trabecular to acinar. When small lumina
are formed between the cells, the pattern becomes micro-
cystic (lattice-like). Table 2 compares this conventional
subtype of AcCC with normal parotid; some of the features
Fig. 4 The cut surface of a nodular ACC shows variegated appear-
ance of hemorrhagic patches and tan or gray, solid areas (a). Another
nodular ACC showing variously cystic cut surface (b)
Table 1 Structural organization of AcCC
Silhouette
Cell arrangements (solid, microcystic, cystic, follicular, papillary,
mixed)
Cell phenotypes (serous, non-serous)
Stroma
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are further described below (see ‘‘Histochemistry and
electron microscopy’’ and ‘‘Immunohistochemistry and
related modalities’’). It is noted that occasional intercalated
duct-like structures may be irregularly/asymmetrically
mixed with serous cell aggregates in conventional AcCCs.
About 77 % of AcCCs are non-solid variants com-
posed of varying proportions of non-serous cells in
microcystic, cystic, follicular, and papillary architectural
arrangements (Figs. 5c, 6b–d), which often present
diagnostic difficulties for the non-specialist. For instance,
follicular AcCC with its follicular-like structures, lined
by cuboidal or flattened epithelial cells containing col-
loid-like secretion [71], may resemble thyroid carcinoma;
small papillary AcCC could be mistaken as papillary
cystadenoma. The non-serous cells are traditionally
regarded as intercalated duct-like cells. They are small,
cuboidal with indistinct borders, scant eosinophilic
cytoplasm and central, lightly stained nuclei with
inconspicuous nucleoli (Fig. 7); denser nuclei are asso-
ciated with follicular arrangements.
Both serous and non-serous cells may show character-
istic cytoplasmic ‘vacuoles’ that probably reflect cyto-
plasmic lumina (see ‘‘Histochemistry and electron
microscopy’’ section (Figs. 6a, 7) and are diagnostically
useful. They may coalesce in AcCCS composed of non-
serous cells, which results in true lumina and microcystic
areas eventually.
In our opinion, the presence of ‘clear’ cells in AcCC has
been overemphasized. Certainly ‘pale’ cells are a feature of
AcCC (Fig. 8a), but they are not extensive and their
cytoplasmic qualities are not those of the ‘empty’ appear-
ing clear cells of mucoepidermoid carcinoma [2]. On these
grounds, purported difficulties in distinguishing ‘clear’ cell
AcCC from hyalinizing clear cell carcinoma or epithelial-
myoepithelial carcinoma do not seem justified.
Apocrine and mucous phenotypes (Fig. 8), mitoses,
microliths [72], and iron uptake/storage (Fig. 9) are occa-
sionally seen in AcCC. Iron uptake/storage may be diag-
nostically useful, but can be seen in salivary adenomas as
well [73]. Similar to mucoepidermoid carcinoma [2],
stromal lymphoid aggregates/benign lymphopoiesis and
cholesterol granulomas are features of AcCC (Fig. 10). The
former may be conspicuous and is well established—
hence, attempts at defining a novel ‘Warthinoid’ subtype of
AcCC do not seem justified.
The characterisation ‘de-differentiated’ or, preferably,
‘AcCC with high-grade transformation’ is used when a
typical low-grade AcCC, primary or metastatic, shows
areas resembling high-grade adenocarcinoma (Fig. 11) or
undifferentiated carcinoma (including small cell carcinoma
types). These lesions may reflect histologic progression and
cannot be identified without areas of typical AcCC
appearance [23, 25, 74]. Whenever dedifferentiation or
undifferentiated areas are observed, clinical outcome is
significantly worse, as reflected by the finding of lymph
node metastasis or the development of distant disease, with
about two-thirds of patients dying from disease after a
median of 4.3 years [25].
Fig. 5 Scanned histological section of AcCC (T) of the palate; the
asymmetrical, lobulated, largely solid and hematoxyphilic (purplish)
tumor appears stemming from a main duct opening onto surface
epithelium (E) (rectangled area); and expands the space between
lamina propia (asterisk), skeletal muscle (M), palatine glands (G) and
tonsil (Ton), but does not extend therein (a). Asymmetrical, lobulated
AcCC (T) partly centred on superficial parotid (P); though largely
solid, the tumor appears less hematoxyphilic than that in (a) because
of increased, eosinophilic (pink) fibrous stroma (asterisk) (b). Largely
cystic AcCC (T) of the parotid (P), which appears less defined than
that in (b); the variably sized cysts contain variously inspissated,
eosinophilic or amphophilic, secretory material
3516 Eur Arch Otorhinolaryngol (2016) 273:3511–3531
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Similar to mucoepidermoid carcinoma [2], AcCC shows
little or no epithelial-mesenchymal transdifferentiation
(EMT) [75].
Histologic features of prognostic significance
and grading
Histologic features of AcCC that may influence prognosis
include: size; silhouette/tumor delineation (circumscribed
versus infiltrative); stromal lymphoid aggregates/tumor
associated lymphoid proliferation (TALP); necrosis; mito-
tic rate determined by examining ten high-power fields
(HPFs) in areas of greatest concentration of mitoses;
atypical mitoses; nuclear pleomorphism; extension beyond
the glandular capsule, although this is inapplicable to
tumors of non-encapsulated minor salivary glands; vascular
and perineural invasion; status of resection margins and
regional lymph nodes; and proliferative index usually
determined by immunohistochemistry for the Ki-67 anti-
gen (also see ‘‘Immunohistochemsitry and related
Fig. 6 Solid growth pattern of serous-like, tumor cells in acinous
arrangements; note the subplasmalemmal, dense nuclei (arrowhead)
and hematoxyphilic cytoplasm with vacuoles (arrows); interstitial
stroma is minimal (a). Microcystic growth pattern; the arrowheads
outline a large aggregate of non-serous tumor cells surrounding
multiple, small, variably rigid lumina containing eosinophilic secre-
tion (L); comparison with (a) allows appreciation of differences in
size, cytoplasmic hue and nuclear position/chromatin pattern between
serous and non-serous tumor cells (b). Follicular growth pattern;
small luminal structures, often rigid and lined by non-serous cells,
contain amphophilic, secretory material with peripheral bubbling as in
thyroid follicles (c). Papillary growth pattern; papillations/tufts of
non-serous cells are supported by hyperaemic cores (d)
Table 2 Morphological
differences between solid,
serous AcCC and normal
parotid tissue
Feature AcCC Parotid
Serous cell phenotype ? ?
Hematoxyphilia of secretory granules Varying Uniform
PAS, amylase reactivities of secretory granules – ?
Arrangement of serous cells Acini, trabeculae, sheets Acini
Cytoplasmic lumina ? –
Striated ducts – ?
Fat – ?
Stroma . m
Eur Arch Otorhinolaryngol (2016) 273:3511–3531 3517
123
Author's personal copy
modalities’’ section) (Fig. 12) [30, 32]. Controversy sur-
rounds the possible significance of architectural arrange-
ments. Spiro et al. [12] suggested that papillary/cystic
patterns are associated with worse survival, but this was not
confirmed by others [13, 32, 35, 71]. Overall, especially
adverse histologic features indicating worse overall/dis-
ease-free survival and loco-regional control (see ‘‘Prog-
nosis’’ and Table 4 therein) are positive resection margins,
extracapsular extension, vascular/perineural invasion,
necrosis, nuclear pleomorphism, high mitotic rate ([2/10
HPFs), atypical mitoses and a Ki-67 index[5 % [30, 32].
Low Ki-67 (\5 %) correlate with TUNEL (terminal
deoxynucleotidyl transferase [TdT]-mediated dUTP-biotin
nick end labeling: identification of DNA breaks in apop-
totic cells) positivity and a good prognosis [76, 77].
In contrast with adenoid cystic carcinoma and mucoepi-
dermoid carcinoma, theWHO has not suggested a histologic
grading system for AcCC [3]. Features mentioned above
would be useful in constructing such a system. Recently, a
‘proliferative grading system’ for AcCC has been suggested,
which distinguishes high- and low-grade tumors based on the
presence of an increased mitotic rate ([2 mitoses/10 HPFs),
necrosis and presence of pleomorphic cells in combination
with extracapsular extension and positive resection margins.
Using this system, the authors classified 35 % of AcCC as
high-grade [32]. Histologic grading is of significance since
high-grade AcCC seems associated with advanced stage
disease, higher incidence of distant metastasis and poorer
outcome [27, 32, 71, 78]. A population-based study analyzed
the prognostic effect of histological grade of AcCC and
reported that patients with low-, moderate or high-grade
tumors showed a 20-year survival of 98, 83, and 38 %,
respectively [28]. Grading would also be useful for indi-
vidualizing treatment; high-grade tumors would opt for high
intensity management. While additional radiotherapy may
be considered for high-grade tumors, patientswith low-grade
tumors would be spared from the morbidity of such inten-
sified treatment [32].
Histochemistry and electron microscopy
Conventional histochemical investigations of AcCC are
mainly concerned with demonstrating mucosubstances in
the cytoplasmic granules of tumor cells. The periodic acid-
Schiff (PAS) positive reaction of those granules, indicative
of the presence of neutral glycoproteins, was firstly
Fig. 7 Cytoplasmic vacuoles (arrows) of non-serous cells. Compare
with Fig. 6a
Fig. 8 Rounded collections of pale cells showing faintly hema-
toxyphilic, fine granules in a clear cytoplasm (a). Apocrine features of
adluminal columnar cells; they show eosinophilic cytoplasm and
intraluminally bulging apex (arrowhead); lymphocytes and extra-
vasated erythrocytes are present in the lumen (b). Mucous cells with
subplasmalemmal nuclei and bubbly hematoxyphilic cytoplasm
(arrowheads) in an aggregate largely composed of non-serous tumor
cells and variably collapsed small lumina (c)
3518 Eur Arch Otorhinolaryngol (2016) 273:3511–3531
123
Author's personal copy
reported by Godwin et al. [4] and is established. The
presence of acidic glycoproteins in AcCC is far less
appreciated, although the classic study by Abrams et al. [9]
noted variable staining of tumor cells with aldehyde
fuchsin and Alcian Blue (AB), indicative of such glyco-
proteins. Figure 13 illustrates patterns of mucosubstance
distribution in AcCC. Staining with tannic acid-phospho-
molybdic acid-Levanol fast cyanine 5RN (TPL), a
technique used for demonstrating normal salivary myoep-
ithelial cells, is not seen [79]. This would accord with the
inconspicuous EMT in AcCC [75].
Fig. 9 Collections of heavily
pigmented/hemosiderin laden
tumor cells (arrowheads) in an
AcCC of the parotid; a nerve
fascicle (N) is seen between the
pushing tumor and normal gland
(a). Perls special staining allows
better appreciation of the extent
of intracellular hemosiderin in
an AcCC with papillary growth
pattern (b)
Fig. 10 Benign lymphopoiesis (asterisk). Tumor (T)
Fig. 11 Metastasis in a cervical lymph node. While much of the
tumor consists of conventional AcCC (asterisk), dedifferentiation/
high-grade transformation to salivary duct carcinoma with ‘Roman
bridging’ is seen (arrowhead). A reniform germinal centre is at the
left of the picture
Fig. 12 Peripheral part of an AcCC of the palate (a); adjacent section
immunostained for Ki67 reveals the high proliferative activity of the
tumor cells (b)
Fig. 13 AcCC stained with Alcian Blue at pH 2.5 followed by
periodic acid-Schiff. A serous-like cell contains neutral and acidic
secretory glycoproteins packed in granules staining royal blue
(arrow). Note the similarly stained glycocalyx of a cytoplasmic
vacuole in a non-serous cell (arrowhead)
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Echevarria’s early electron microscopical investigation
reported on the effects of preservation in effecting ‘clear’
cell phenotypes and illustrated complex phagosomes in
tumor cells [80]. Later investigations using material
specifically preserved for electron microscopy described
variations in the electron density of the cytoplasmic gran-
ules in tumor cells [80–82]. These granules (Fig. 14) usu-
ally lack the complex polypartite substructure
characterizing the secretory granules of normal salivary
glands [83], but preservation nuances should be considered
before conclusions are drawn. The presence of phagosomes
in tumor cells has been confirmed [82, 84], and can be
attributed to lysosomal events and phagy. This is supported
by an electron microscopical cytochemical investigation of
AcCC, which demonstrated lysosomal enzyme activity in
tumor cells laden with secretory granules [85]. Recent
electron microscopical investigations illustrate occasional
‘myoepithelial’ cells at the periphery of tumor cell aggre-
gates [82, 84]. This should not detract from the notion of
inconspicuous EMT in AcCC, as limited sampling is an
inherent limitation of electron microscopy and the obser-
vations are inconsistent with the results of TPL-histo-
chemistry [79] and immunohistochemistry (see below).
Dardick et al. [84] paid particular attention to the micro-
cystic architectural arrangements in AcCC and interpreted
them as intercalated duct-like structures. Chaudhry et al.
[82] were able to provide electron micrographs of cyto-
plasmic lumina in tumor cells, which support their corre-
spondence with the histologically seen cytoplasmic
vacuoles. Myosin adenosine triphosphatase activity relates
to formation of lumina in mammalian salivary glands [86]
and an electron microscopical cytochemical investigation
of that enzyme in AcCC would be thus of interest. Secre-
tory granules suggestive of neuroendocrine differentiation
have been electron microscopically demonstrated in an
AcCC of the parotid [87].
Immunohistochemistry and related modalities
The literature is extensive and as in mucoepidermoid car-
cinoma, the WHO refrains from attempting a meaningful
review [2, 3]. The present article is not intended as a
conventional review of the immunohistochemistry of
AcCC and the following brief discussion is based on ref-
erences selected in view of the various arguments.
Studies concerned with comparing expression of various
secretory components between AcCC and normal salivary
glands, reported variable amylase, lactoferrin, secretory
piece and proline-rich protein immunoreactivities in the
tumor, whereas lysozyme is rarely expressed [88]. Notably,
despite histologic similarities between normal serous acini
and serous-like tumor cells, amylase is not regularly
expressed in AcCC.
The results of immunohistochemically assessing
cytoskeleton/cytoplasmic filaments correspond with the
patterns of tumor differentiation (see ‘‘Histogenesis and
animal models’’). Cytokeratin (CK) ‘cocktails’ are gradu-
ally superseded by staining for individual CKs. The basic
CK7 and acid CK19, which are of low molecular weight
and reflect simple glandular phenotypes, are often expres-
sed in AcCCs of intercalated duct-like cells in microcystic,
cystic, follicular or papillary architectural arrangements;
based on CK7 staining and analogous to CK7 expression in
normal salivary gland epithelia, three distinct histogenetic
subtypes of AcCC are recognized: acinar differentiation as
seen in blue dot tumors (CK7-negative), ductal differenti-
ation as seen in papillary-cystic tumors (diffuse CK7-pos-
itive) and mixed ductulo-acinar (10–66 % CK7-positive
cells) differentiation [71]. Staining for CK7 is not seen in
solid AcCCs of serous-like cells [71]. AcCC (both low- and
HG components) stain with the same intensity using
pankeratin antibodies AE1/AE3 and CK18. Cytokeratins
CK5/6, CK7, and CK19 are expressed in low-grade AcCC,
but not in HG components. CK14 and CK20 are absent in
AcCC [25]. Abundant secretory granules in the latter may,
however, effect attenuation/displacement of the
cytoskeleton and affect detection of immunoreactivities.
Myofilament-associated smooth muscle actin or calponin
immunoreactivities have not been reported in AcCC [89],
which accords with the results of TPL-histochemistry and
inconspicuous EMT in AcCC [75, 79]. Vimentin also
seems absent [90].
Fig. 14 Electron micrograph of serous-like cell in AcCC fixed in
glutaraldehyde/osmium tetroxide and stained with uranyl acetate and
lead citrate. Variously dense secretory granules are at the left part of
the rounded nucleus. Mitochondria and rough endoplasmic reticulum
are at the right part. The arrow indicates a phagosome. Golgi
complex (G)
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Novel markers have recently reinforced the particular
patterns of differentiation in AcCC. The chloride channel
DOG1 (Anoctamin-1, described in gastrointestinal stromal
tumors—GIST1), selectively expressed in the luminal
plasmalemma of serous acinar and intercalated ductal cells
and the transcriptional activator SOX10 expressed in nuclei
of those cells, are variously immunolocalized in AcCC [91,
92]. Positive DOG1 staining can be an admixture of apical
membranous, cytoplasmic, and complete membranous
staining, and would support AcCC versus many differential
diagnoses. This differential diagnosis includes MASC, but
biphasic tumors like, e.g. adenoid cystic carcinoma and
epithelial-myoepithelial carcinoma can also express
DOG1, although to a lesser degree and lower intensity than
AcCC [91, 93].
Controversy surrounds the expression of plasmalemma-
anchored, epithelial membrane antigen (MUC1) in AcCC.
While Gusterson et al. [94] did not record any immunore-
activity, later studies reported regular staining [95]. Of other
plasmalemmal molecules, AcCC shows variable membra-
nous staining for CD44 and integrin avb3 [96].
Lysosomal events and phagy in AcCC have already
been considered (see ‘‘Histochemistry and electron
microscopy’’ section). In this vein, an immunohistochem-
ical study demonstrated widespread, cytoplasmic, and
apical expression of CD63, a glycoprotein of lysosomal
membranes, in serous-like and non-serous tumor cells,
respectively (Fig. 15), and around microliths [97]. The
findings can be attributed to lysosomal processing and/or
auto-/heterophagy of secretory material.
It is generally regarded that S-100 protein is not
expressed in AcCC [98]. The significance of this rather
unpretentious feature is now increasingly appreciated (see
‘‘Differential diagnosis’’ and ‘‘Proposed classification’’).
Immunohistochemistry confirmed aberrant neuroen-
docrine differentiation in few AcCCs [87, 99–102]. This
may result in a paraneoplastic syndrome [103], but is
probably a pathological curiosity.
Except for the S-100 protein immunoreactivities, the
above features seem largely academic. The following
molecular biological aspects can, however, be useful in
grading and prognosis.
Molecules associated with the cell cycle are firstly
considered. We have already commented on the signifi-
cance of the Ki67 index (see ‘‘Histologic features of
prognostic significance and grading’’). The Ki-67 index, an
independent prognosticator for all SGCs [76, 104, 105], is
markedly increased (Ki-67 index up to 60 %) in AcCC
with high-grade transformation, where high expression of
cyclin D1 is also seen [25]. In contrast with the Ki-67
index, argyrophilic nucleolar organizer region-associated
proteins (AgNORs) have not been found of prognostic
value in AcCC [106]. Apoptosis assessed by immunohis-
tochemistry for bcl-2 protein and TUNEL, seems more
pronounced in Stage I AcCC and overexpression of p53
(nuclear staining [10 %) is low [107]. Recently, the
mammalian target of rapamycin (mTOR), significant in the
homonymous signaling pathway that regulates cell cycle
and promotes proliferation, has been variously
immunolocalized in AcCC [108, 109].
Growth factor receptors are now considered. A study
using a tissue microarray reported epidermal growth factor
receptor (EGFR, HER-1) immunoreactivity in 30 out of
168 AcCCs (17.9 %), which varied from weak to strong
[110], whereas a conventional immunohistochemical study
reported weak staining in three out of 6 tumors [109].
Overexpression of epidermal growth factor receptor 2
(HER-2/neu, ErbB-2) is less common (one out of 170,
0.59 %) [111]. In situ hybridization, however, suggests that
HER-2/neu is overexpressed at the mRNA level in AcCC
[112]. In an in vitro situation, targeting overexpressed Her-
2 with Gefitinib has resulted in cytostasis in one AcCC
derived cell line [113].
Of proteins involved in DNA damage repair, p53 protein
is usually not detected in LG components, but strongly
expressed ([50 %) in the HG areas of AcCC. P63, a p 53
homologue, has recently been proposed to differentiate
AcCC (no expression) from MEC (nearly always positive)
[114]. The MEC-specific CRTC1–MAML2 gene fusion is
another useful biomarker that distinguishes MEC from
AcCC [115].
Little is known about expression of sex hormone
receptors in AcCC, which precludes from assessing any
therapeutic/prognostic correlations. An institutional study
reported immunoreactivity for androgen receptors in two
out of ten tumors [116].
Fig. 15 CD63 immunoreactivity in AcCC. Serous-like tumor cells
show strong, granular, cytoplasmic staining around vacuoles (a); non-
serous cells surrounding lumina (L), show strong staining of the apical
cytoplasm (b)
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Cytophotometry and flow cytometry
In contrast with mucoepidermoid carcinoma [2, 117],
cytophotometry quantified DNA does not correlate with the
clinical course of AcCC [117, 118]. In addition, prognosis
seems similar for tumors with diploid or aneuploid DNA
assessed by flow cytometry [106, 119].
Differential diagnosis
We have already alluded to potential problems (see ‘‘His-
tology’’). Diagnosis of solid AcCC with largely serous-like
cells would not pose significant problems for the aware
general pathologist with adequate exposure to salivary
pathology while in training. AcCC of non-serous cell in
various architectural arrangements is completely the
opposite. Even novices in oral/head and neck pathology
would experience difficulties and frustration. Detection of
cytoplasmic vacuoles would almost be diagnostic for the
experienced specialist and other clues (e.g., hemosiderin
pigmentation) would be helpful. Standard references offer
appropriate advice on the traditional differential diagnosis
of AcCC from the perspective of trainees/non-specialists
[18, 69] and we further comment on particular aspects.
Largely unicystic, AcCC with stromal lymphoid aggregates
may be misinterpreted as lymphoepithelial cyst on casual
inspection [60, 67], but any invasive growth in the ‘wall’ of
the cystic structure and/or intraluminal papillations should
be alerting. Difficulties in distinguishing follicular and/or
papillary AcCC from salivary metastases of thyroid carci-
nomas may have been overemphasized; such metastases
are rare; when in doubt the characteristic nuclear features
of papillary thyroid carcinomas (overlapping, ‘empty’
appearance, grooves, pseudoinclusions) should be sought
and immunohistochemistry (thyroglobulin etc.) may not be
even necessary. In our opinion, unduly attention has been
paid to the role of immunohistochemistry for p63 and CK5/
6 in differentiating AcCC from salivary oncocytoma; [120]
recognition of oncocytic features is rather straightforward
on hematoxylin and eosin stained sections of good quality
and solid AcCCs of non-serous, eosinophilic cells are rare.
Occasionally, however, there are difficulties in distin-
guishing microcystic and follicular AcCC from mucoepi-
dermoid carcinoma with inconspicuous mucous/squamoid
cells as both tumors may appear variously cystic/papillary
with simple, eosinophilic cells and stromal, lymphoid
aggregates. In this case, immunohistochemistry for p63 is
recommended, as staining would be present in intermedi-
ate/non-descript cells of mucoepidermoid carcinoma and
usually absent from AcCC [114, 121].
Currently, the greatest diagnostic challenge is differen-
tiating AcCC from MASC. As MASC is histologically
similar to microcystic/papillary AcCC of non-serous cells,
[21, 22, 122–128] distinction usually relies on special
techniques. It has been reported that MASC cells lack PAS-
positive secretory granules [122, 126], but this is a matter
of dispute. In addition, pathologists trained in the present
era, where diagnostic immunohistochemistry and molecu-
lar testing reign, may have difficulties in interpreting
conventional mucosubstance histochemistry. Immunohis-
tochemistry seems more helpful as staining for vimentin,
S-100 protein, proteins related to secretory mechanisms
(STAT5a and mammaglobin) and adipophilin (a compo-
nent of milk lipid globule membranes) is usually positive in
MASC, though negative in AcCC [21, 123, 127, 129].
Immunostaining should always be interpreted in conjunc-
tion with routine histology as S-100 protein and mamma-
globin immunoreactivities are features of other SGCs [130,
131]. In addition, nuclear staining for the transcription
factor GATA3 is another feature associated with MASC,
but not with conventional AcCC [132]. Caution should also
be exerted as regards staining with adipophilin [126] and
cross-immunoreactivity with lipid-rich residues of lysoso-
mal events/phagy (see ‘‘Histochemistry and electron
microscopy’’ and ‘‘Immunohistochemistry and related
modalities’’) should be considered. A definite diagnosis of
MASC can only be established via demonstration of the
chromosomal t(12;15) (p13;q25) translocation, which
results in fusion between the ETV6 gene on chromosome
12 (a transcription regulator) and the NTRK3 gene on
chromosome 15 (a membrane receptor kinase influencing
cell proliferation and survival) [126]. This genetic re-ar-
rangement, usually demonstrated by means of ETV6 fluo-
rescence in situ hybridization (FISH) [124, 127, 128], is not
found in other SGCs [21, 133–135]. Chiosea et al. [125]
detected ETV6 translocation in so-called ‘zymogen granule
poor AcCCs’, but they subsequently re-classified them as
MASC.
It should be appreciated that FISH and antibodies for
mammaglobin or DOG1 may not be available to all
pathology laboratories. We therefore recommend that all
salivary tumors with a histologic appearance of non-serous,
microcystic/papillary AcCC are routinely immunostained
for S-100 protein. If staining is negative, a diagnosis of
AcCC should be established; if staining is positive and in
the absence of more specific tests, the pathologist should
raise the possibility of MASC and explain the situation in
his/her report. The nuances in distinction may be academic
to clinicians as both conventional AcCC and MASC share
a similar outcome [125].
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Histogenesis and animal models
Although proliferative capacity lies with all types of sali-
vary glandular cells [72], the origin of AcCC has been
traditionally sought among purported, ‘semipluripotential
reserve’ or ‘stem’ cells located at the acinar-intercalated
ductal region of salivary glands; proliferation and abnormal
cytodifferentiation of those cells would result in AcCC [7,
23, 136, 137]. Chaudhry et al. [82] attributed ‘pluripoten-
tial reserve/stem’ qualities to simple tumor cells with a
high nuclear:cytoplasmic ratio and few organelles. Overall
interpretations of electron microscopical observations [82,
84] and the immunohistochemical localization of DOG1
and SOX10 in AcCC [92, 94], as discussed above, suggest
that the histogenesis of AcCC simulates events at the ends
of branching rudiments during salivary embryogenesis. In
this regard, we may envisage the histology of AcCC (see
above) as a continuum. At one end would be AcCC of
simple duct-like cells (intercalated duct-like or incom-
pletely differentiated acinar) in microcystic or other
architectural arrangements, whereas at the other end would
be solid AcCC of differentiated serous-like cells; AcCC of
varying proportions of duct-/serous-like cells possibly
occupies a middle position and myoepithelial differentia-
tion is not prominent. Interestingly, the acinar differentia-
tion seems functional as in vitro tumor cells secrete
amylase when stimulated by adrenalin [48, 138, 139]. The
features in S1 can be reconciled with this histogenetic
model; AcCC may spread to involve main ducts and acini
emptying into proximal extralobular ducts have been
described in mammalian salivary glands [138].
Little is known about naturally occurring, animal mod-
els for the study of human salivary tumors. However, 70 %
of male transgenic (MMTV/v-Ha-ras) mice develop tumors
in their parotids, which show electron microscopic features
and immunohistochemical expression of amylase similar to
those of AcCC [140]. The model is of interest, but has not
enjoyed widespread endorsement and further application.
Of greater clinical potential appears the deletion of both the
Adenomatous Polyposis Coli (APC) and Phosphatase and
tensin homologue (PTEN) tumor suppressor genes in mice,
which results in activation of the mTOR pathway and
formation of salivary gland tumors resembling human
AcCC with 100 % penetrance; treatment with the rapa-
mycin inhibited mTOR and led to complete regression of
tumors, which indicates dependence of growth on sustained
signaling [141]. The results allow pondering whether
treatment with mTOR inhibitors may benefit AcCC
patients, given immunohistochemical confirmation of
activated mTOR signaling in human AcCC [108, 109].
Genetics
The genetic landscape of AcCC is insufficiently explored.
In the Mitelman database of Chromosome Aberrations and
Gene Fusions in Cancer there are only 11 cases with
cytogenetic alterations published (http://cgap.nci.nih.gov/
Chromosomes/Mitelman). Early investigations showed
alterations, often loss of heterozygosity, in 84 % out of 25
AcCCs frequently altered regions being on 4p and 17p,
followed by 5q and 6p [142]. The only recurrent changes
observed are extra copies of chromosome 8 and deletions
or translocations with breakpoints in 6q13-q24. Terminal
6q-deletions are a typical feature of all major subtypes of
SGCs [143]. A single AcCC showed deletions in the tumor
suppressor CDKN2A and proapoptotic cofactor of p53-
encoding PPP1R13B; and mutations in the cell growth
regulator EP300 [144]. Given the possible significance of
the PTEN-activated mTOR signaling pathway (see ‘‘Im-
munohistochemistry and related modalities’’ and ‘‘Histo-
genesis and animal models’’) [108, 109, 141], the sporadic
association of AcCC with the effected by germline muta-
tions of PTEN, Cowden syndrome (see ‘‘Epidemiology’’)
[42] is of interest. The situation regarding the ETV6–
NTRK3 fusion is still evolving (see ‘‘Differential diagno-
sis’’ and ‘‘Proposed classification’’).
Proposed classification
The academically meritorious discovery of ETV6 re-ar-
rangement in tumors histologically similar to microcystic
AcCC of non-serous cells and the introduction of the
MASC concept (see ‘‘Definition and brief historical sur-
vey’’ and ‘‘Differential diagnosis’’) has excited much
interest [21]; [22, 122–128]. There are over 40 related
publications in the PubMed data base (http://www.ncbi.
nlm.nih.gov/pubmed). The histologic similarities and
increased availability of ETV6 FISH prompted institutional
re-examination of cases previously diagnosed as AcCC.
While non-serous tumors of microcystic and papillary
architectural arrangements were thus re-classified as
MASC, solid tumors of serous cells did not harbor the
characteristic gene re-arrangement [22, 125, 145]. Further
corroboration is desirable, but the results suggest re-clas-
sifying salivary tumors with MASC and ‘serous cell ade-
nocarcinoma’ (an old term aptly describing solid AcCC of
serous-like cells) featuring as distinct entities. Breast
pathologists support distinguishing secretory from acinic
cell carcinoma [133] and pending rigorous epidemiological
testing, MASC and AcCC may show an opposite gender
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distribution (male-to-female ratio 8:2) as compared to
AcCC (male-to-female ratio, 1:1.5) [27, 28, 37, 125].
Alternatively, AcCC lacks a bimodal age pattern (see
‘‘Epidemiology’’); it may be imprudent playing down his-
tologic and prognostic similarities between AcCC and
MASC; [125] a particular genetic alteration may not be
detected in every tumor, e.g. the MAML2 re-arrangement is
seen in 50–70 % of mucoepidermoid carcinomas; [2] reg-
ular expression of DOG1 or SOX10 in every AcCC would
be unrealistic; and high-quality electron microscopical
investigations of MASC are urgently needed, particularly
in view of observations regarding adipophilin immunore-
activity and lysosomal events/phagy (see ‘‘Differential
diagnosis’’) [97, 127]. A sensible compromise in keeping
with current knowledge and arguments for and against re-
classification is shown in Table 3. The approach, based on
the continuum discussed under ‘‘Histogenesis and animal
models’’, suggests a family of tumors rather than distinct
entities; is centered on the established term AcCC, though
in the modified form of ‘acinic-intercalated ductal carci-
noma’ to smooth away the apprehensive notion of AcCCs
largely composed of cells lacking obvious secretory gran-
ules (see ‘‘Definition and brief historical survey’’); and
would be more palatable to clinicians concerned about
intricacies of histologic classifications.
Management
Surgery: the primary tumor
As AcCCs are often anatomically accessible tumors and
patients do not show distant metastases at presentation, the
treatment of choice would be complete resection aiming at
achieving free margins, thereby avoiding post-operative
morbidity [35, 54]. AcCC may be, however, initially
underestimated, as indicated by the high number of redo-
cases in a recent study [36].
Surgery alone will likely be curative for low-grade
AcCC. The extent of the operation should parallel the loco-
regional anatomical extent of the tumor as influenced by
the site of origin. Although superficial parotidectomy often
effects complete removal, more extended, conservative
parotidectomy is indicated if the deep lobe is involved. A
pre-operatively functioning facial nerve can be preserved
without loss of oncologic control, even if there would be no
margin between tumor and nerve, and any microscopic,
residual disease seems treatable with post-operative
radiotherapy [54]. A more aggressive, initial approach
would be required for locally advanced AcCCs, especially
pre-operatively known high-grade tumors in risk of posi-
tive margins, bone/nerve invasion, and nodal metastases. A
pre-operatively paralyzed or grossly invaded/surrounded
facial nerve should be resected and reconstructed with an
interposition graft from the greater auricular or sural nerve.
Advanced cases may also require resection of skin, poste-
rior mandible/masseter or lateral temporal bone, followed
by a free flap reconstruction. In AcCC of minor salivary
glands, local anatomy will dictate the best surgical
approach [47].
Surgery: the neck
Elective ND in patients with AcCC is usually not recom-
mended because of a relatively low incidence of regional
lymph node metastasis (10 %). The MDACC study, how-
ever, observing that addition of an ND to the surgical
strategy decreases the rate of regional recurrences, suggests
that patients with large tumor volume or tumors with high-
grade features in the pre-operative biopsy would likely
benefit from elective ND of levels II, III and IV [36].
Clinically positive cervical lymph nodes at presentation
are an adverse prognosticator necessitating therapeutic ND
as part of the surgical approach and should raise suspicion
of an AcCC with HG transformation.
Radiotherapy
Low grade, low stage (I and II), and adequately resected
AcCCs are not considered for radiotherapy, as their prog-
nosis is excellent with surgery alone [54, 146]. This is
supported by a recent SEER analysis specifically assessing
any oncologic benefits of additional radiotherapy [147].
The study did not demonstrate an effect of post-operative
radiotherapy on stage I and II, low-grade AcCC; no dis-
ease-specific deaths were recorded in 50 stage I, low-grade
tumors treated with surgery alone.
Criteria for additional radiotherapy do not differ from
those for other SGCs [54] and include salvage surgery for
recurrent disease; advanced T-classification (T3/T4); pos-
itive surgical margins; pathologically positive, cervical
lymph nodes; perineural invasion; and high-grade/highly
proliferative tumors [28, 32, 36]. Patients with prognosti-
cally worse AcCC selected to undergo post-operative
radiotherapy through application of those criteria, doubled
Table 3 The acinic-intercalated ductal carcinoma family
Solid acinic cell carcinoma of serous-like cells (‘Serous cell
adenocarcinoma’)
Carcinomas of various proportions of acinic and intercalated duct-
like cells
Carcinomas of intercalated duct-like cells in microcystic,
papillary, follicular, cystic and mixed architectural arrangements
S-100 protein (–) ? consider immunohistochemistry for DOG1
S-100 protein (?)/MASC ? consider immunohistochemistry
for mammaglobin, ETV6 FISH
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their chance of staying disease-free when thus treated (HR
of 2, p = 0.04) in multivariate analysis).
Conversely, the SEER analysis undertaken by Biron
et al. [44] concludes that ‘radiotherapy probably is not
effective in AcCC’; the study even suggests and that after
multivariate correction for stage and grade, radiotherapy
implied a death hazard ratio of 2. Caution should be,
however, exerted as it is imprudent to retrospectively
assess the value of a ‘treatment’. It is noted that the SEER
analysis does not correct for involved resection margins or
initially inadequate treatment, which account for a sub-
stantial part of AcCC patients [36] and would probably end
up being radiated. Missing data in the variables corrected
for, are further weakening the conclusions; for instance,
although the analysis spanned from 1973 to 2009, precise
TNM classification had only been obtained for patients
from 2000 to 2005 [44]. In other words, even after cor-
rected ‘‘roughly’’ for stage and grade, significant selection
and information bias still is likely present in the retro-
spective SEER data, resulting from the reality that hard-to-
capture prognostic factors have usually been incorporated
in a clinical decision to add radiotherapy to the treatment of
early stage AcCC that worries the treating oncologist.
Chemotherapy
Little is known regarding chemotherapy in AcCC. The
potential value of mTOR inhibitors has already been
mentioned (see ‘‘Histogenesis and animal models’’), but no
specific chemotherapeutic agents have been currently
approved. Nevertheless, an observed distant metastasis rate
of 1 in 5 (most commonly in the lungs) indicates the need
for developing such treatment [36].
Prognosis
Endorsing the outlined therapeutic strategies (see ‘‘Man-
agement’’), AcCC is generally considered to have the best
survival rate among SGCs, although the subgroup with
high-grade transformation has a poorer prognosis [28]; [27,
148, 149]. AcCC is by no means an innocent tumor. Earlier
studies reported that the cure rate decreased from 76 to
89 % at 5 years to 55 % at 15 years and 56 % at 20 years
[150], similar trends being noted by others [12, 13]. The
evidence suggests a protracted clinical course with recur-
rences occurring years or even decades after initial diag-
nosis and treatment (mean time to recurrence, 92 months)
[32, 35, 66]. Clearly, this can be an aggressive tumor that
should be treated accordingly and appropriate initial
treatment would thus obviously affect prognosis. Mere
enucleation is totally inadequate [12, 151] and this has
been recently corroborated by multivariate analysis [36].
The effects of selectively applied post-operative radio-
therapy have been discussed above (see ‘‘Management’’)
[54, 146, 152]. A recent institutional study indicates a
median survival of 28.5 years, with only 13 out of 155
patients (8.4 %) dying of their disease (mean time to death
from disease, 3.8 years; range, 0.7–11.2 years) [36].
Selection/referral bias obviously affects institutional results
as large tertiary/referral centers a usually end with prog-
nostically worse cases and a higher proportion of patients
with either residual or recurrent disease after suboptimal
initial treatment. Nevertheless, better results are now being
reported. Recent population-based studies indicate overall
5-, 10-, and 20-year survival of 97, 94, and 90 %, respec-
tively; survival dropped to 22 % in patients with distant
metastasis [28].
Prognostic factors considered as significant are shown in
Table 4. They include age; [36] pain; [35] gender, AcCC
being probably the sole SGC where this appears significant;
[28, 36] race, with colored individuals having a worse
outcome; [28] previous inadequate treatment; [36] extent
of disease (advanced T-classification, invasion of tumor
beyond glandular capsule, advanced N classification); [13,
28, 32, 35, 36, 44] and especially invasion of the skull base
[153]. In a series from the Mayo clinic, lateral skull base
invasion, mainly direct extension of tumor through the
stylomastoid foramen, occurred in one of ten patients, in
80 % of these following local recurrence [153]. Of note,
following skull base recurrences, also low-grade AcCC had
a fatal outcome, and only one in two patients with this
feature made it through the next 2 years [153].
Invasion of the anterior skull base is uncommon and
typically associated with the rare sinonasal AcCC. Anterior
skull base invasion is infrequently seen, typically in the
rarely occurring sinonasal AcCC. However, sinonasal ori-
gin as such does not seem to carry a worse prognosis, as
evidenced from the 18 cases in the SEER database that
were matched to major salivary gland AcCC [154]. A
general idea of the effect of UICC/AJCC stage on outcome
in the largest series reported to date is that Stage I tumors
carry a 93.5 % 20 years DSS, Stage II tumors a 98 %
20 years DSS, Stage III tumors and Stage IV tumors a
64 % 20 years DSS [44]. Disease-specific deaths are not
uncommon in the course of AcCC; In a recent series,
76.9 % of those were attributable to distant metastases
[32].
Of the factors considered above, the MDACC multi-
variate analysis regards the following factors as influencing
overall and disease-free survival in AcCC: gender, inade-
quate previous treatment (these patients have a signifi-
cantly higher chance of succumbing to disease and a hazard
Ratio of recurrence twice as high as that of advanced vs
low stage disease), extent of disease (T-classification,
UICC/AJCC stage), positive resection margins and age at
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Table 4 Adverse
prognosticators in AcCC
Factor Univariate identification of
prognostic value of factor for
different outcomes
Multivariate confirmation of
prognostic value of factor for
different outcomes
Patient
Increasing age OS (36)
DSS (27)
OS (36)
Pain at presentation DFS (35)
Male gender OS (28, 35, 36, 44) OS (28, 36, 44)
Non-caucasian race OS (28) OS (28)
Tumor
Anatomic site
Minor salivary gland origin DSS (44) DSS (44)
Anatomic extent
T classification OS (30, 32, 36, 71, 158)
DFS (12, 13, 36)
DSS (158)
OS (36)
DFS (36)
N classification DSS (27, 28, 35)
DFS (13, 32)
DSS (28)
OS (36)
M classification OS (28, 36)
DSS (27)
OS (28)
Stage DFS (30, 71)
DSS (44)
DSS (44)
Macroscopic invasion beyond
glandular capsule
DFS (13, 32)
DSS (35)
Macroscopic invasion of VIIth
nerve
OS (32)
Skull base invasion DFS (154)
Histopathology
Tumor grade
Proliferative grading (32)
Increased mitoses (13, 35)
DSS (27)
OS (28, 32, 71)
DFS (32, 35)
DSS (44, 158)
DSS (28)
DSS (44)
Histological extracapsular
extension
DFS (32)
LRC (32)
OS (32)
Irradical resection DFS (13)
OS (32, 36)
DFS (32)
OS (36)
Desmoplastic stromal
reaction/lymphoid stroma
DFS (35)
Perineural invasion DFS (30, 32)
LRC (32)
Vascular invasion DFS (30)
DFS (32)
Treatment
Previous inadequate treatment OS (36)
RFS (36)
DFS (13, 35)
OS (36)
RFS (36)
Additional radiotherapy
(controversial findings)
DSS worse (44)
DSS better survival for high grade
AcCC if additional radiotherapy
(27)
DFS better (36)
DFS worse (44)
OS overall survival, DSS disease specific survival, DFS disease free survival, LRC locoregional control,
RFS recurrence free survival
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diagnosis [36]. With the exception of gender, these factors
had already been identified and confirmed in other studies
dealing with all types of SGCs [26, 155, 156]. Gender did
not feature as a significant prognostic factor in the SEER
analysis of Biron et al. [44]. In the latter analysis, the
factors remaining in multivariate analysis were advanced
stage (HR 2), minor salivary gland subsite (HR 3) and HG
(HR 3.3 for grade III and 8.1 for grade IV).
Epilog
Our perception of salivary AcCC has been repeatedly
modified over the 12 decades since its description. Successes
include the introduction of modern imaging modalities in the
assessment of patients; application of various morphological
methodologies to characterize cellular phenotypes/events
suggestive of distorted embryonic development; and multi-
variate analyses of population-based datasets/institution-
based series indicative of factors influencing prognosis,
management, and outcome. In addition, molecular method-
ologies introduced the concept of MASC and prompted
further thinking and research. Uncertainties, however,
remain. Links between particular genetic alterations and
cellular phenotypes reflecting abnormal events at the ends of
branching salivary rudiments should be explored; the role of
the S-100 protein in salivary pathobiology should be clari-
fied; and high-grade transformation and patterns of nodal
metastasis should be precisely characterized. Prospects are
good, but would require continuous research efforts in the
hope that non-invasive therapies and gene manipulation may
become available in future.
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